Publication date: Jul 12, 2023
IMPORTANCE Treatment options for coronavirus disease 2019 (COVID-19) that can be used irrespective of risk factors for severe disease are warranted. OBJECTIVE To assess the efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19. DESIGN The phase 3 part of a phase 2/3, double-blind, randomized, placebo controlled study conducted from February 10 to July 10, 2022. SETTING A multicenter study conducted at 92 institutions in Japan, Vietnam, and South Korea. PARTICIPANTS Patients (aged 12 to
| Concepts | Keywords |
|---|---|
| Coronavirus | Covid |
| Gyeonggi | Efficacy |
| July | Ensitrelvir |
| Microbiology | Japan |
| July | |
| Medrxiv | |
| Mild | |
| Moderate | |
| Ph | |
| Phase | |
| Preprint | |
| Randomized | |
| Safety |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 |
| disease | MESH | Infectious Diseases |
| disease | VO | USA |
| disease | VO | titer |
Download Document
(Visited 1 times, 1 visits today)